Research programme: SSAO inhibitors and substrates - Acorda Therapeutics
Latest Information Update: 02 Mar 2017
$50 / €47 *
At a glance
- Originator Biotie Therapies Corp.
- Mechanism of Action Amine oxidase (copper-containing) inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 26 Mar 2009 Preclinical trials in Diabetes mellitus in Finland (unspecified route)